The most frequent mutation was TET2 (85%) in AITL patients, PCLO (40%) in PTCL-NOS patients, TP53 (25%) in ALK + ALCL patients, and TP53 (50%) in ALK- ALCL patients (Fig. 1). This evidence concerns the gene TP53 and mature T-cell and NK-cell non-Hodgkin lymphoma.